Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,131.20
(
0.48%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
100.65
(
2.39%
)
Bitcoin
74,282.84
(
-0.75%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 92044

Wednesday, 04/21/2010 2:28:34 PM

Wednesday, April 21, 2010 2:28:34 PM

Post# of 257253
ASCO will have something on the potentially registrational phase-2 trial of ABT-888 in Stage III/IV melanoma, according to today’s ABT CC. This is the trial in question:

http://clinicaltrials.gov/ct2/show/NCT00804908

ABT-888 is a dual PARP inhibitor that ABT acquired in the Facet Biotech deal.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now